Abstract 19613: Role on Late Gadolinium Enhancement in Non Ischemic Cardiomyopathy - A Meta Analysis
Background: Patients with non-ischemic cardiomyopathy (NICM) have high mortality due to sudden cardiac deaths from hemodynamically significant ventricular arrhythmias (VA). This is due to the presence of myocardial fibrosis and/or scarring. Late gadolinium enhancement (LGE) has been shown to predict the presence of myocardial fibrosis. We performed a meta-analysis to evaluate the role of LGE in patients with NICM.
Methods: A systematic literature search was performed in PubMed and EMBASE database for clinical trials evaluating LGE in NICM. All cause mortality, cardiac mortality and major arrhythmic events (defined as VA and sudden cardiac deaths from VA) outcomes were evaluated. We conducted meta-analysis assuming random effects by using RevMan (Version 5.3.5 Copenhagen, Denmark). Results were calculated with 95% CI and was considered statistically significant if 2[[Unsupported Character - Codename ­]]sided alpha error was <.05.
Results: A total of 23 studies (n=5,282) were included in the meta-analysis. Average follow-up was 33 months. Average age of the included population was 54.4 ± 2.3 years. Presence of LGE has shown to predict all cause mortality (OR 2.75 [1.72-4.40], P <0.0001), cardiac mortality (OR 3.37 [1.93-5.88], P <0.0001), cardiac related hospitalizations (OR 2.74 [1.51-4.98], P = 0.0009), major arrhythmic events including sudden cardiac deaths (OR 4.12 [3.05- 5.57], P <0.00001).
Conclusion: Presence of LGE would be helpful in identifying patients who are at high risk for major arrhythmic events including sudden cardiac deaths. LGE is also helpful in predicting mortality and hospitalizations in patients with NICM.
Author Disclosures: A. Kannan: None. K. Prudhvi: None. G. Chamarthi: None. G. Kutti-Sridharan: None. R. Janardhanan: None.
- © 2016 by American Heart Association, Inc.